<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738347</url>
  </required_header>
  <id_info>
    <org_study_id>GE-180-001</org_study_id>
    <nct_id>NCT01738347</nct_id>
  </id_info>
  <brief_title>Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).</brief_title>
  <official_title>Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Probe Development and Commercialization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the
      Imaging Protocol of GEH120714 (18F) Injection. Study recruits healthy volunteers and
      participants with relapsing and remitting multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recording the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.</measure>
    <time_frame>Time zero equals the date of contrast imaging and for up to 24 hours for safety monitoring post contrast administration.</time_frame>
    <description>Record the occurrence of adverse events (AEs) to evaluate the safety of a single dose of GEH120714 (18F) Injection in healthy volunteers (HV) and participants with rrMS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood samples collected multiple periods post injection; and urine samples at periods post injection to count radioactivity to determine bio-distribution, internal radiation dosimetry and Effective Dose (E) in healthy volunteers (HV).</measure>
    <time_frame>Time zero equals the date of contrast imaging and up to the evaluation of the images and the kinetic modelling of cerebral uptake of GEH120714 (18F) Injection,</time_frame>
    <description>Collect blood samples at multiple time periods up to 120 minutes post drug injection; and urine samples at multiple time periods up to 270 minutes post drug injection to count radioactivity to determine the bio-distribution, internal radiation dosimetry and Effective Dose (E) per protocol in healthy volunteers (HV).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis (rrMS)</condition>
  <arm_group>
    <arm_group_label>Arm 1 - GEH120714 (18F) Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 1 - GEH120714 (18F) Injection</intervention_name>
    <description>Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).</description>
    <arm_group_label>Arm 1 - GEH120714 (18F) Injection</arm_group_label>
    <other_name>GEH120714 (18F)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for all Participants:

          -  The subject has a clinically normal or acceptable medical history and physical
             examination at screening.

          -  The subject has an acceptable kidney function (eGFR &gt;60 mL/min/1.73m2) for
             administration of Gadolinium.

          -  The subject has a trans-locator protein (TSPO) platelet assay conducted with
             documented results.

        Inclusion Criteria for all healthy volunteers:

          -  The subject has no clinical history or signs of neurological impairment.

          -  The subject has a normal MRI without central white white matter lesions.

        Inclusion Criteria specific for participants with relapsing and remitting results sclerosis
        (rrMS):

          -  Subject with a previous diagnosis of rrMS, presenting with (a) clinically active
             disease at time of screening or, or preferentially, (b) clinically active disease at
             time of screening and having at least one gadolinium--enhanced lesion on MRI.

          -  The subject at screening has a MRI scan of sufficient quality for Volume of Interest
             (VOI) definition and co-alignment with Positron Emission Tomography (PET).

        Exclusion Criteria:

        General Exclusion Criteria for all participants:

          -  The subject has a contraindication for Magnetic Resonance Imaging (MRI).

          -  The subject has known allergies to Gadolinium contrast agent.

          -  The subject has received significant ionising radiation exposure from clinical trials
             or medical examinations in the last 12 months.

        Exclusion Criteria specific for healthy volunteers:

          -  The subject has family history of multiple sclerosis (MS).

          -  The subject is undergoing monitoring of occupational ionising radiation exposure.

        Exclusion Criteria specific for participants with remitting multiple sclerosis (rrMS):

          -  The subject has a past history of cerebrovascular disease or vasculitis.

          -  The subject has a history of head injury with prolonged coma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sherwin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

